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• Transplant indications and assessment.
Cirrhosis is end stage of chronic liver 
disease of different etiologies
• HCV, Alcohol NASH most 
common
• Characterized by bridging 
fibrosis and nodules in biopsy
• Compensated cirrhosis may 
be asymptomatic
• Decompensated disease has 
50 -80% 5 year mortality 
• 12th most common cause of  
death in US 
• Rising burden: HCV, HCC, 
Obesity




• Percutaneous exposure to blood. 
• Birth Cohort
• Blood products < 1992, 
• Tattoos,  
• Clotting factors < 1987, 
• Hemodialysis, 
• Needle sticks in HCW, 
• Shared needles with Injection drug 
use, 
• Shared straws with nasal drug use, 
• Incarceration, 
• health care with poor infection 
control
• HBV:  Endemic areas
Identifying Cirrhosis in Primary Care 
Setting
• Early cirrhosis is asymptomatic
• Suspect Liver disease/cirrhosis 
if 
• there are risk factors (Alcohol, 
Viral, Metabolic syndrome, FH)
• Spider nevi, palmar erythema, 
Terry’s nails, gynecomastia 
Dupeytrens contractures, firm 
sharp edged liver, splenomegaly. 
• Persistently abnormal liver tests 
(especially AST > ALT) 
• LOW PLATELETS 
Establish Cirrhosis with Liver Biopsy 
(specialist/Radiology) or Non-invasively
• Liver BX is invasive, costly, with risk 
and poorly accepted 
• Alternatives to liver Bx: 
• APRI score  = (AST/40)/Plts*100
• Fib-4 score = (AST*Age)/(Plts*√(ALT))
• Fibrosure – blood test
• Fibroscan: blind elastic recoil US
• US (enhanced shear wave) – augmented U/S test
• MRE – Magnetic Resonance Elastography
• Stage 3-4 fibrosis /cirrhosis Rule of 12: 
• Spleen > 12 cm
• Portal Vein > 12 mm
• Platelets < 12 ^2 (144)

Initial Management of the Cirrhotic Patient Includes 
General Health, Education and Secondary Prevention 
1. Identify and Treat Etiology
2. Identify and manage co-mobidities  that may lead to progression 
(alcohol, HIV  obesity )
3. Health education and secondary prevention. (HBV HCV Genetic 
etc)
4. Vaccination against flu and pneumonia, hepatitis A and B virus
5. Treat associated conditions (nutrition, diabetes, osteoporosis, 
malnutrition.)
• Promote family and cohabitants’ participation to primary prevention and 
help remove barriers/ impediments to transplant
• substance dependence 
• Social support
• Identify and correct medical issues 
Education and intervention to reduce 
progression 
1. Establish etiology and comorbidities (HIV HBV HCV )
2. Abstinence /cessation of alcohol consumption 
3. Obesity
4. Establish degree of fibrosis to determine the need for 
initiating additional screening measures (eg, 
hepatocellular carcinoma [HCC] screening). 
5. Make sure patient is treated for any treatable etiology 
(refer, if you do not treat)
Treating the Disease May Reverse  












530 patients with advanced fibrosis, treated 
with interferon-based therapy, and followed 
for 8.4 (IQR 6.4-11.4) years 
Fibrosis reduced on Serial biopsy on 
Treating Hepatitis B 
Treat Cause of Liver Disease
• Alcoholic liver disease
• Hepatitis B: Tenofovir, entecavir. 




Important to establish the diagnosis accurately wherever possible

General Measures
• Manage Substance dependence: 
• Obesity
• Social:  Caregiver support: especially for hepatic 
encephalopathy 
• Debility: conditioning (physical therapy)
General Measures:  Immunizations and 
Nutrition
• Cirrhotic patients are Immune compromised and have 
special vaccination requirements (same as >65) 
• Hepatitis A
• Hepatitis B
• Pneumococcal: PConjugateV13 or PPolysaccherideV23 should 
receive a single dose of PCV13 followed by a dose of PPSV23 at 
least 8 weeks later. PPSV23, at least 5 years after the most recent 
dose of PPSV23.
• Annual Influenza 
(http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html
accessed 4/14/15)
• Frequent small meals
• Do not skip meals
• Bedtime ensure Plus or 
snack
• Protein: 1-2 g/kg BW-
Do Not restrict for HE. 
• Na restriction < 
2000mg/d for ascites
• Fluid Restriction if 
dilutional hyponatremia
Lindsay D. Plank et al Nocturnal Nutritional Supplementation Improves Total Body Protein Status of patients with Liver Cirrhosis: a 
Randomized 12-Month Trial HEPATOLOGY 2008;48: 557-566
Verboeket-van de Venne WP,. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food 
intake. Gut. 1995;36(1): 110-116
Cirrhosis: Protein Calorie and Micronutrient 
deficiency, and Catabolic in Post-Absorptive State
Improved Total Body Protein with 
16oz  Ensure + (474 cc, 26g protein 710 kcal)
HCC Surveillance  Every 6 months (US and 
AFP)- 3-5% Annual HCC Incidence in Cirrhosis
HCC screening in Cirrhosis








• Chronic hepatitis B carriers: males aged 40 y and females aged 50 y
• family history of hepatocellular cancer in chronic hepatitis B.
Surveillance algorithm
Figure. A proposed liver ultrasound algorithm for surveillance of 
hepatocellular carcinoma.
Gish, R. ,Gastroenterology & Hepatology, 
2014; 10;2:121-123. 
a. See LI-RADS at http://www.acr.org/Quality-
Safety/Resources/LIRADS.
b. Blood tests AFP-L3/DCP (HCC serum biomarkers).
c. AASLD Guidelines 2009.

Prognosis: MELD and Child Score
MELD Model for End Stage Liver 
Disease:10X [0.957  Ln (Creat [mg/dL]) 











Prognosis is Poor  After Index Event:  Liver 
Transplant Evaluation 
• Liver transplant evaluation in all patients with 
decompensated liver disease (Child’s≥ B).
• compensated cirrhosis: 91% 5 year survival.  
• If index event: (Bleed, ascites, HE, renal insufficiency): <50% 5yr 
survival
(Fattovitch Gastro 97; 112: 463)
Absolute Contra-indications to TP : 
competing risks of Death
• Uncontrolled infection
• Extra-hepatic malignancy
• Active substance or alcohol dependence.
• Severe cardiopulmonary disease. 
• Severe pulmonary hypertension.
• Inability to follow immunosuppressive therapy.
Relative Contra-indications: relatively 
competing risks of death
• Advanced Hepatocellular carcinoma (>Stage 3A)
• Cholangiocarcinoma (except stage 1)
• Advanced age (>70yrs)
• Portal vein thrombosis.
• Insufficient social support.  
• HIV : 
• In selected HIV-infected recipients post transplant survival similar 
to that of HIV-negative recipients.
• Survival without transplant worse
• OLT considered if there is no history of opportunistic infections or 
neoplasms, CD4 cell count >100 cells/mm3, and plasma HIV viral 




• Spontaneous Bacterial Peritonitis 
• Varices/ prevent Hemorrhage
• Hepatic Encephalopathy
Ascites Management
• Diagnostic paracentesis: in every patient. (TP, Alb Cell 
Count Diff (Triglycerides).  
• Dietary salt restriction (Education)
Fluid loss depends on negative sodium balance (water 
loss follows)
• 2g sodium/day (88mmol)  
• Diuretics 
• Spironolactone 100 –300 (400) mg/day and 





• Tense ascites (hemodynamic improvement).
• Renal insufficiency (compartment syndrome).
• Refractory ascites
• Up to 5 liters may be safely removed sans albumin.  
However, preferable to use 8g albumin IV per liter ascites 
removed.




















PPS: Progressive rise in Renin and very high mortality

Transjugular Intrahepatic 
Portosystemic shunting Versus 
Paracentesis Plus albumin for 




The North American Study for 




Refractory Ascites Equally Managed 
Using TIPS or Taps. Stop Beta Blockers.
Deleterious effects of beta-blockers on survival in patients 
with cirrhosis and refractory ascites. Sersté T. Hepatology. 
2010 Sep;52(3):1017-22
Sodium Restriction is for Hypervolemia, 
Water restriction is for Hyponatremia
• RAAS and increased 
aldosterone









• Often present with:
• Encephalopathy,  GI bleeding,  diarrhea, renal 
impairment  non-specific symptoms of infection.
• May not have.
• Peritoneal signs, fever, pain.
• Prognosis.
• 50% mortality in 1 year.
• Two thirds have recurrence in 1 year.
• DP: admission, (in hospital for any 
deterioration or bleed)
SBP Laboratory
T e s t  R e s u l t  I n t e r p r e t a t i o n  
 
Polymorphonuclear  
> 500/mm3 SBP (97% specific) 
cell count >250 <500 SBP (95% specific) 






• Albumin (1.5g/kg bw day 1, and 1g/kgbw day 3)
Treatment SBP: Antibiotics
• Empiric therapy initiated at time of diagnosis.
• Cefotaxime 2g q 8-12hrs. (Ceftriaxone protein 
bound diminished penetration) 
• May narrow spectrum once sensitivities are 
available
• Treatment: 5 days (similar outcome to 10 day 
therapy)











Renal Imp Death In Hosp 3m death
No Alb
Albumin
P< 0.002 P<0.01 P<0.03
Sort, P.  NEJM: 341 403-9
SBP Prophylaxis:  Indications
• Previous episode of SBP (1 yr 40-70% 
recurrence)
• Ascites total protein < 1g/dl (20-40% incidence  
in 1 year)
• Bilirubin > 2.5 mg/dl (1 yr 43%)
• If NO prior SBP, alb>1g/dl and bili< 2.5: risk for 
SBP 
• 1year 0% 
• 3 year 3%
SBP Prophylaxis
• Antibiotic choices (all given po)
• Norfloxacin, 400mg/d; Fluoro-quinolone resistance possible: local 
resistance pattern
• Trimethoprim-cotrimoxazole DS 5 days/week
• Meta-analysis:  Survival advantage 
• Life expectancy after SBP: 1 yr 30-50% 2yr 25-30%)

LONGACRE & GARCIA-TSAO Clin Liver Dis 10 (2006) 613–625
Algorithm for Prevention of Variceal 
Hemorrhage in Cirrhosis 
Antibiotic Choice in GI Bleeder
Proven infections
Possible infections
Antibiotic choice: IV gives better levels.  Choice depends on likely organisms 
(resistance patterns etc.  
Oral Norflox and Levoflox no longer antibiotics of choice. 

Hepatic Encephalopathy
• A spectrum of reversible neuropsychiatric abnormalities in 
patients with liver disease1,2 or portosystemic shunting3
• Symptoms may range from subtly altered mental status to 
deep coma4,5
• Marked by alternating periods of acute exacerbation and 
remission6
• Occurs in up to ~50%7 to 70%8 of patients with cirrhosis
1. Blei and Córdoba. Am J Gastroenterol. 2001;96:1968-1976. 2. Mullen et al. Semin Liver Dis. 2007;27(suppl 2):32-48. 3. Mas. 
Digestion. 2006;73(suppl1):86-93. 4. Riordan and Williams. N Engl J Med. 2010;362:1140-1142. 5. de Melo et al. Am J Health-Syst
Pharm. 2008;65:818-822. 6. Merck. http://www.merck.com/mmhe/sec10/ch135/ch135f.html?qt=hepatic encephalopathy&alt=sh. 
Accessed April 6, 2010. 7. Guevera et al. Am J Gastroenterol. 2009;104:1382-1389. 8. Prasad et al. Hepatology. 2007;45:549-559. 
Delirium or Neuropsychiatric Changes in 
Cirrhotic possibly dt Hepatic Encephalopathy
• Rule out other etiologies of delirium or coma (Alcohol, 
sedatives, Drugs, Electrolyte abnormalities, 
hypoglycemia, subdural hematoma, seizures)
• Establish precipitant 
• Hypovolemia, Hypokalemia (too much lactulose), infection, GI 
Bleed, Over diuresis, constipation, dietary protein excess (red 
meat)
• Supportive care (fall precautions, monitoring, IV fluids)
• Treat/remove precipitant
• Lactulose (Avoid overdosing: diarrhea is counter 
productive)
• Rifaximin 550 bid. 

Minimal Hepatic Encephalopathy (Covert) does 
not have overt signs but is debilitating 
• Combination of psychometric test (number connection 
tests (NCTs) A and B, the digit symbol test, and the block 
design test,+  computerized psychometry, critical flicker 
frequency test, inhibitory control.
• It is common and affects quality of life
• Increases risk of accidents. 
Bajaj JS , Navigation skill impairment:another dimension of the driving 
difficulties in minimal hepatic encephalopathy. Hepatology 2008 ; 47 : 596 – 604
Diagnosis MHE
• Combination of psychometric test (number connection 
tests (NCTs) A and B, the digit symbol test, and the block 
design test,+  computerized psychometry, critical flicker 
frequency test, inhibitory control.
• Abnormal tests predict impaired navigational skills in 
cirrhotic patients tested in a driving simulator. 
Bajaj JS , Navigation skill impairment:another dimension of the driving 
difficulties in minimal hepatic encephalopathy. Hepatology 2008 ; 47 : 596 – 604
Minimal Hepatic Encephalopathy increases 
Driving Risk and reduces QOL. 
Treatment MHE
• Non-absorbable disaccharide lactulose and 
probiotics are effective. Antibiotics improve MHE. 
• The non-absorbed and safe antibiotic rifaximin 
has now been shown to improve psychometric 
test performance scores and concomitantly 
improve HRQOL in patients with MHE. 
Prasad S Lactulose improves cognitive functions and HRQOL in minimal hepatic 
encephalopathy . Hepatology 2007 ; 45 : 549 – 59
Sidhu S. Rifaximin improves Psychometric Performance and Health Related Quality of Life in Patients 
with Minimal Hepatic Encephalopathy (The RIME trial) .Am J Gastroenterol 2011;106:307–16

